BERKELEY, CA, USA (Press Release) - March 11, 2009 - Learn about new markers for the diagnosis and management of transitional cell carcinoma of the bladder.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Objectives: At the end of the program, participants will be able to describe:
- the common presentations of superficial bladder cancer
- the role of urine cytology in the diagnosis and management of transitional cell carcinoma of the bladder
- newer techniques for evaluating urinary sediment for cancer cells.
Date: April 2, 2009
Time: 12 pm EDT, 11 am CDT, 10 am MDT, 9 am PDT
For registration, click here.
If you have questions call: 1-800-421-7110 ext. 6696
Who should attend:
Physicians, laboratorians and other healthcare professionals interested in diagnosis and management of bladder cancer
Barry S. Stein, MD
Krisnamurthi Family Professor and Chief of Urology Brown Medical School.
1 hour of free CME credit will be provided.
[ PRESS RELEASE ]